Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation
Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu, Evie H Carchman · 2026
Read Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation by Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu, Evie H Carchman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13623110.txt.
Description
Lele Chang and co-authors test a drug pairing for recurrent or metastatic cervical cancer that carries a PIK3CA mutation, a common gene change. The pairing combines immune checkpoint inhibitors, which release the immune system to attack tumours, with tyrosine kinase inhibitors, which block growth signals. No standard approach targets this mutation group.
Data came from two prospective trials plus hospital records, covering fifty-five patients. Twenty-seven received the pairing and twenty-eight received doctor-chosen conventional treatment. Tumours shrank in most patients on the pairing, more often than on conventional care, and the time before cancer grew again more than doubled. Survival leaned the same way without reaching statistical ground. Side effects such as high blood pressure, rash, and thyroid problems were more common with the pairing but were managed, with no treatment-related deaths. The authors call the results a strong case for larger trials.
Catalog record
| CREATOR | Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu, Evie H Carchman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |